AutoImmune deal

The first project is a Phase II trial testing AI-401's ability to halt the progression of newly onset Type I diabetes. The cost of the trials would depend on the size of the patient enrollment, which hasn't been determined, but Hennessey estimated that the trial costs could run about $20 million.

Lilly has agreed to develop future generations of oral tolerance products for autoimmune-mediated diseases as well. ...